Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App





Rapid COVID-19 Test Uses Graphene-Enhanced Sensor to Produce Signal After Positively Identifying Viral Antigens

By HospiMedica International staff writers
Posted on 04 Aug 2020
A new COVID-19 rapid test delivers accurate and reliable results in seconds using a graphene-enhanced sensor that produces a signal when exposed to COVID-19 viral antigens.

The graphene-enhanced sensor has been developed by Graphene Leaders Canada (GLC) Inc. More...
(Alberta, Canada) together with its subsidiary GLC Medical (GLCM) Inc. for use in their Rapid COVID-19 Virus Detection Test Kit. The only of its kind saliva test eliminates the nasopharyngeal swab, all certified practitioner oversight requirements, does not require expensive equipment, and there is no cross handling which increases cross contaminations. GLCM's test directly detects the virus ensuring no false positive/negative results, unlike other tests which detect only the byproducts of infection and are therefore unreliable.

GLCM has completed development of the graphene-enhanced sensor used in the rapid test kit, which is an in-vitro diagnostic device that produces a signal when exposed to COVID-19 viral antigens. Following the achievement of the positive identification of the viral antigens, GLCM has commenced development of a functional prototype of the rapid-response test. GLCM's COVID-19 point-of-care test will offer a unique advantage over other tests as it detects the presence of the COVID-19 virus. GLCM's test has been developed to indicate a positive result only when the COVID-19 virus is present, allowing for direct and clear interpretation by the user. GLCM's rapid test is an "at the door" technology which is perfect before boarding a plane, entering a venue for a concert or sporting event, as it delivers instant results regaining confidences to bring us back to our "normal" before the pandemic. The company is advancing discussions with manufacturers and governments in several countries in order to facilitate production protocols reflective of their country's government regulatory compliance requirements.

"Graphene is the ideal sensing material. The 2D nature and conductive attributes of graphene make for an extremely sensitive material to detect any molecule," said Jason Deacon, Product Development Lead of GLC-GLCM. "I have investigated this principle extensively during my time at Cambridge University. At GLC-GLCM, we have made the surface highly specific to SARS-CoV-2 (COVID-19) to ensure that our rapid test will save lives. The study of 2D materials has been encased in academia for 15 years. Our team at GLC-GLCM believes that nanotechnology regarding 2D materials is critical to future technology and innovation, with graphene at the forefront".

"The success of this development offers the world a solution for COVID-19, and as our graphene is tailorable, we can offer a fast solution to future virus' in rapid modification of our graphene which will ensure we do not relive the major economic shutdown as experienced with COVID-19," said Donna Mandau, President & CEO for GLC-GLCM. "The inspiration for all of us at GLC-GLCM is to offer our graphene solutions for People and Planet. This rapid test brings family and friends together for times of joy free from fear of COVID-19. This test also brings family together in those times that we need to say good-bye to a loved one. No one should have to die alone again."

Related Links:
Graphene Leaders Canada (GLC) Inc.


Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Mammo DR Retrofit Solution
DR Retrofit Mammography
IV Therapy Cart
Avalo I.V Therapy Cart
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.